Increasing the COVID-19 immunization rate through allergy testing.
Journal
Journal of the European Academy of Dermatology and Venereology : JEADV
ISSN: 1468-3083
Titre abrégé: J Eur Acad Dermatol Venereol
Pays: England
ID NLM: 9216037
Informations de publication
Date de publication:
Jun 2023
Jun 2023
Historique:
received:
10
10
2022
accepted:
01
02
2023
medline:
15
5
2023
pubmed:
23
2
2023
entrez:
22
2
2023
Statut:
ppublish
Résumé
Vaccination of the population is required to combat the COVID-19 pandemic. Allergy testing could reduce anxiety towards COVID-19 vaccination and thereby may increase vaccination rate, however, its effectiveness remains unclear. One hundred and thirty prospective real-life patients in need of but not daring to get vaccinated asked for allergy workup for COVID-19 vaccine hypersensitivity in 2021/2022. Characterization of patients, identification of anxieties, decrease of patient's anxiety levels, overall vaccination rate and adverse reactions after vaccination were assessed. Tested patients were characterized by being female (91.5%) and having a high rate of previous allergies (e.g. to food 55.4%, drugs 54.6%, or previous vaccinations 50%) and dermatological disease (29.2%) but not always had medical contraindications for COVID-19 vaccination. Sixty one patients (49.6%) were highly concerned (4-6, Likert scale 0-6) about vaccination and 47 (37.6%) expressed resolving thoughts about vaccinaion anaphylaxis (3-6, Likert scale 0-6). However only 35 patients (28.5%) were scared of getting COVID-19 within 2 months (4-6, Likert scale 0-6) and only 11 (9%) patients had high expectations of getting COVID-19 (4-6, Likert scale 0-6). Allergy testing significantly (p < 0.01 to p < 0.05 respectively) reduced the median anxiety of allergic symptoms following vaccination: dyspnoea (4.2-3.1), to faint (3.7-2.7), long-term consequences (3.6-2.2), pruritus (3.4-2.6), skin rash (3.3-2.6) and death (3.2-2.6). After allergy testing, most patients (108/122, 88.5%) let themselves be vaccinated within 60 days. Revaccinated patients with previous symptoms experienced a reduction of symptoms (p < 0.05) upon revaccination. Patients not daring to get vaccinated have more anxiety towards vaccination than to acquire COVID-19. For those, allergy testing excludes vaccine allergy, and is a tool to increase vaccination willingness and thereby helps to combat vaccination hesitancy.
Sections du résumé
BACKGROUND
BACKGROUND
Vaccination of the population is required to combat the COVID-19 pandemic. Allergy testing could reduce anxiety towards COVID-19 vaccination and thereby may increase vaccination rate, however, its effectiveness remains unclear.
METHODS
METHODS
One hundred and thirty prospective real-life patients in need of but not daring to get vaccinated asked for allergy workup for COVID-19 vaccine hypersensitivity in 2021/2022. Characterization of patients, identification of anxieties, decrease of patient's anxiety levels, overall vaccination rate and adverse reactions after vaccination were assessed.
RESULTS
RESULTS
Tested patients were characterized by being female (91.5%) and having a high rate of previous allergies (e.g. to food 55.4%, drugs 54.6%, or previous vaccinations 50%) and dermatological disease (29.2%) but not always had medical contraindications for COVID-19 vaccination. Sixty one patients (49.6%) were highly concerned (4-6, Likert scale 0-6) about vaccination and 47 (37.6%) expressed resolving thoughts about vaccinaion anaphylaxis (3-6, Likert scale 0-6). However only 35 patients (28.5%) were scared of getting COVID-19 within 2 months (4-6, Likert scale 0-6) and only 11 (9%) patients had high expectations of getting COVID-19 (4-6, Likert scale 0-6). Allergy testing significantly (p < 0.01 to p < 0.05 respectively) reduced the median anxiety of allergic symptoms following vaccination: dyspnoea (4.2-3.1), to faint (3.7-2.7), long-term consequences (3.6-2.2), pruritus (3.4-2.6), skin rash (3.3-2.6) and death (3.2-2.6). After allergy testing, most patients (108/122, 88.5%) let themselves be vaccinated within 60 days. Revaccinated patients with previous symptoms experienced a reduction of symptoms (p < 0.05) upon revaccination.
CONCLUSIONS
CONCLUSIONS
Patients not daring to get vaccinated have more anxiety towards vaccination than to acquire COVID-19. For those, allergy testing excludes vaccine allergy, and is a tool to increase vaccination willingness and thereby helps to combat vaccination hesitancy.
Substances chimiques
COVID-19 Vaccines
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1228-1235Subventions
Organisme : Bavarian State Ministry for Science and Art
ID : H.4001.1.7-53-7-TUME-FME-DE0BK.
Informations de copyright
© 2023 The Authors. Journal of the European Academy of Dermatology and Venereology published by John Wiley & Sons Ltd on behalf of European Academy of Dermatology and Venereology.
Références
Altmann DM, Boyton RJ. COVID-19 vaccination: the road ahead. Science. 2022;375(6585):1127-32.
Johns Hopkins University. Coronavirus Resource Center. Available from: https://coronavirus.jhu.edu. Accessed August 04, 2022.
Andrews N, Stowe J, Kirsebom F, Toffa S, Rickeard T, Gallagher E, et al. Covid-19 vaccine effectiveness against the omicron (B.1.1.529) variant. N Engl J Med. 2022;386(16):1532-46.
Eyre DW, Taylor D, Purver M, Chapman D, Fowler T, Pouwels KB, et al. Effect of Covid-19 vaccination on transmission of alpha and Delta variants. N Engl J Med. 2022;386(8):744-56.
Bjork J, Bonander C, Moghaddassi M, Rasmussen M, Malmqvist U, Inghammar M, et al. COVID-19 vaccine effectiveness against severe disease from SARS-CoV-2 omicron BA.1 and BA.2 subvariants - surveillance results from southern Sweden, December 2021 to march 2022. Euro Surveill. 2022;27(18):2200322.
Bent R, Faihs V, Tizek L, Biedermann T, Zink A, Brockow K. PEG allergy - a COVID-19 pandemic-made problem from a German perspective. World Allergy Organ J. 2022;15:100714.
Shaker M, Abrams EM, Greenhawt M. A cost-effectiveness evaluation of hospitalizations, fatalities, and economic outcomes associated with universal versus anaphylaxis risk-stratified COVID-19 vaccination strategies. J Allergy Clin Immunol Pract. 2021;9(7):2658-68 e3.
Sampath V, Rabinowitz G, Shah M, Jain S, Diamant Z, Jesenak M, et al. Vaccines and allergic reactions: the past, the current COVID-19 pandemic, and future perspectives. Allergy. 2021;76(6):1640-60.
Worm M, Ring J, Klimek L, Jakob T, Lange L, Treudler R, et al. Covid-19 vaccination and risk of anaphylaxis - recommendations for practical management. MMW Fortschr Med. 2021;163(1):48-51.
Rasmussen TH, Mortz CG, Georgsen TK, Rasmussen HM, Kjaer HF, Bindslev-Jensen C. Patients with suspected allergic reactions to COVID-19 vaccines can be safely revaccinated after diagnostic work-up. Clin Transl Allergy. 2021;11(5):e12044.
Greenhawt M, Abrams EM, Shaker M, Chu DK, Khan D, Akin C, et al. The risk of allergic reaction to SARS-CoV-2 vaccines and recommended evaluation and management: a systematic review, meta-analysis, GRADE assessment, and international consensus approach. J Allergy Clin Immunol Pract. 2021;9(10):3546-67.
Bent R, Faihs V, Darsow U, Biedermann T, Brockow K. Organisation und Erkenntnisse einer Pilotstudie zur allergologischen Abklärung einer COVID-19 Impfstoff Allergie in der Weihnachtswoche 2021. Allergologie. 2022;45:812-22.
Klimek L, Jutel M, Akdis CA, Bousquet J, Akdis M, Torres MJ, et al. ARIA-EAACI statement on severe allergic reactions to COVID-19 vaccines - an EAACI-ARIA position paper. Allergy. 2021;76(6):1624-8.
Shimabukuro TT, Cole M, Su JR. Reports of anaphylaxis after receipt of mRNA COVID-19 vaccines in the US-December 14, 2020-January 18, 2021. JAMA. 2021;325(11):1101-2.
Team CC-R, Food, Drug A. Allergic reactions including anaphylaxis after receipt of the first dose of Pfizer-BioNTech COVID-19 vaccine - United States, December 14-23, 2020. MMWR Morb Mortal Wkly Rep. 2021;70(2):46-51.
Volpp KG, Loewenstein G, Buttenheim AM. Behaviorally informed strategies for a national COVID-19 vaccine promotion program. JAMA. 2021;325(2):125-6.
Sallam M. COVID-19 vaccine hesitancy worldwide: a concise systematic review of vaccine acceptance rates. Vaccines (Basel). 2021;9(2):160.
Barbaud A, Garvey LH, Arcolaci A, Brockow K, Mori F, Christoballina M, et al. Allergies and COVID-19 vaccines: an ENDA/EAACI position paper. Allergy. 2021;77(8):2292-2312.
Bonadonna P, Brockow K, Niedoszytko M, Elberink HO, Akin C, Nedoszytko B, et al. COVID-19 vaccination in Mastocytosis: recommendations of the European competence network on Mastocytosis (ECNM) and American initiative in mast cell diseases (AIM). J Allergy Clin Immunol Pract. 2021;9(6):2139-44.
Klimek L, Bergmann KC, Brehler R, Pfützner W, Zuberbier T, Hartmann K, et al. Practical handling of allergic reactions to COVID-19 vaccines: a position paper from German and Austrian allergy societies AeDA, DGAKI, GPA and ÖGAI. Allergo J Int. 2021;30(3):79-95.
Brockow K, Mathes S, Fischer J, Volc S, Darsow U, Eberlein B, et al. Experience with polyethylene glycol allergy-guided risk management for COVID-19 vaccine anaphylaxis. Allergy. 2021;77(7):2200-2210.
Faihs V, Bent R, Darsow U, Biedermann T, Brockow K. Tolerance to SARS-CoV-2 mRNA vaccination in a patient with challenge-confirmed PEG 2000 allergy. J Investig Allergol Clin Immunol. 2022;33(2).
Mathes S, Eberlein B, Darsow U, Faihs V, Vitus M, Bent R, et al. Variability of eliciting thresholds in PEG allergy limits prediction of tolerance to PEG-containing mRNA COVID vaccines. J Allergy Clin Immunol Pract. 2022;10(7):1931-3.
Picard M, Drolet JP, Masse MS, Filion CA, ALMuhizi F, Fein M, et al. Safety of COVID-19 vaccination in patients with polyethylene glycol allergy: a case series. J Allergy Clin Immunol Pract. 2022;10(2):620-5.e1.
Patterson NJ, Paz-Soldan VA, Oberhelman R, Moses L, Madkour A, Miles TT. Exploring perceived risk for COVID-19 and its role in protective behavior and COVID-19 vaccine hesitancy: a qualitative study after the first wave. BMC Public Health. 2022;22(1):503.
Banerji A, Norton AE, Blumenthal KG, Stone CA Jr, Phillips E. Rapid progress in our understanding of COVID-19 vaccine allergy: a cause for optimism, not hesitancy. J Allergy Clin Immunol. 2022;150(1):12-6.
Greenhawt M, Abrams EM, Oppenheimer J, Vander Leek TK, Mack DP, Singer AG, et al. The COVID-19 pandemic in 2021: avoiding Overdiagnosis of anaphylaxis risk while safely vaccinating the world. J Allergy Clin Immunol Pract. 2021;9(4):1438-41.
Stone CA Jr, Rukasin CRF, Beachkofsky TM, Phillips EJ. Immune-mediated adverse reactions to vaccines. Br J Clin Pharmacol. 2019;85(12):2694-706.
Caubet JC, Ponvert C. Vaccine allergy. Immunol Allergy Clin North Am. 2014;34(3):597-613. ix.
Yasmin F, Najeeb H, Moeed A, Naeem U, Asghar MS, Chughtai NU, et al. COVID-19 vaccine hesitancy in the United States: a systematic review. Front Public Health. 2021;9:770985.
Soost S, Leynaert B, Almqvist C, Edenharter G, Zuberbier T, Worm M. Risk factors of adverse reactions to food in German adults. Clin Exp Allergy. 2009;39(7):1036-44.
World Health Organization (WHO). Ten Threats to Global Health in 2019. 2019 Available from: https://wwwwhoint/news-room/spotlight/ten-threats-to-global-health-in-2019 (accessed on 01 August 2022).
Bendau A, Plag J, Petzold MB, Strohle A. COVID-19 vaccine hesitancy and related fears and anxiety. Int Immunopharmacol. 2021;97:107724.